Rafferty Asset Management LLC Has $2.72 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

Rafferty Asset Management LLC boosted its stake in shares of Edwards Lifesciences Co. (NYSE:EWGet Rating) by 5.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 20,984 shares of the medical research company’s stock after buying an additional 1,110 shares during the period. Rafferty Asset Management LLC’s holdings in Edwards Lifesciences were worth $2,718,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of EW. Liberty Wealth Management LLC raised its holdings in Edwards Lifesciences by 362.3% during the 3rd quarter. Liberty Wealth Management LLC now owns 245 shares of the medical research company’s stock worth $29,000 after buying an additional 192 shares during the period. EverSource Wealth Advisors LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $29,000. Northwest Investment Counselors LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $30,000. Arlington Partners LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $34,000. Finally, Mascoma Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $38,000. Hedge funds and other institutional investors own 82.54% of the company’s stock.

Shares of EW stock opened at $97.39 on Wednesday. Edwards Lifesciences Co. has a 12 month low of $88.96 and a 12 month high of $131.73. The firm has a market cap of $60.55 billion, a PE ratio of 39.91, a price-to-earnings-growth ratio of 2.95 and a beta of 1.16. The stock has a 50 day moving average of $111.77 and a 200-day moving average of $114.24. The company has a quick ratio of 2.64, a current ratio of 3.41 and a debt-to-equity ratio of 0.10.

Edwards Lifesciences (NYSE:EWGet Rating) last issued its quarterly earnings results on Tuesday, April 26th. The medical research company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.02. Edwards Lifesciences had a return on equity of 25.80% and a net margin of 28.72%. The company had revenue of $1.34 billion during the quarter, compared to analyst estimates of $1.31 billion. During the same period in the previous year, the company earned $0.54 earnings per share. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. As a group, equities analysts predict that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

In related news, VP Catherine M. Szyman sold 20,000 shares of the company’s stock in a transaction on Friday, February 18th. The stock was sold at an average price of $106.31, for a total value of $2,126,200.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Larry L. Wood sold 7,242 shares of the company’s stock in a transaction on Tuesday, May 10th. The shares were sold at an average price of $96.13, for a total value of $696,173.46. Following the completion of the transaction, the vice president now owns 206,069 shares of the company’s stock, valued at $19,809,412.97. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 250,031 shares of company stock valued at $26,973,194. Corporate insiders own 1.29% of the company’s stock.

A number of brokerages have recently weighed in on EW. Piper Sandler dropped their target price on Edwards Lifesciences from $133.00 to $125.00 in a report on Thursday, January 27th. Raymond James dropped their target price on Edwards Lifesciences from $134.00 to $126.00 and set an “outperform” rating on the stock in a report on Thursday, January 27th. Morgan Stanley lowered their price target on Edwards Lifesciences from $148.00 to $136.00 and set an “overweight” rating for the company in a research note on Thursday, January 27th. Stifel Nicolaus lowered their price target on Edwards Lifesciences from $132.00 to $120.00 and set a “buy” rating for the company in a research note on Thursday, January 27th. Finally, Zacks Investment Research raised Edwards Lifesciences from a “sell” rating to a “hold” rating and set a $115.00 price target for the company in a research note on Friday, April 29th. Five equities research analysts have rated the stock with a hold rating and twenty-one have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $127.50.

About Edwards Lifesciences (Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Further Reading

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWGet Rating).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.